Single photon emission computed tomography tracer

Recent Results in Cancer Research

Volumn 187, Issue , 2013, Pages 65-105

  Müller, Cristina ^a   Schibli, Roger ^a,b  

^a ETH Zurich   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ARGINYLGLYCYLASPARTIC ACID; BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; COPPER 67; CYANOCOBALAMIN; FIBRONECTIN; FLUORODEOXYGLUCOSE F 18; FOLIC ACID; GALLIUM 67; GLUCAGON LIKE PEPTIDE 1; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; LUTETIUM 177; MOLYBDENUM 99; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTENSIN DERIVATIVE; PENTETATE INDIUM IN 111; PENTETREOTIDE; RHENIUM 186; RHENIUM 188; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; THYMIDINE KINASE; TRACER; DIAGNOSTIC AGENT; IMMUNOGLOBULIN FRAGMENT; VITAMIN;

ARTICLE; CHELATION; CHEMICAL STRUCTURE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOSCINTIGRAPHY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR WEIGHT; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERMODYNAMICS; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; METHODOLOGY; REVIEW;

HUMANS; IMMUNOGLOBULIN FRAGMENTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VITAMINS;

EID: 84871843006     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10853-2_2     Document Type: Article

References (195)

1. Abrams MJ, Juweid M et al (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31:2022-2028
2. +. J Am Chem Soc 123:3135-3136
3. - in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 120:7987-7988
4. 99mTc. J Am Chem Soc 121:6076-6077
5. + (M = Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev 192:901-919
6. Alford R, Ogawa M et al (2009) Molecular probes for the in vivo imaging of cancer. Mol BioSyst 5:1279-1291
7. Alshoukr F, Rosant C et al (2009) Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors. Bioconjug Chem 20:1602-1610
8. + moiety. Nucl Med Biol 33:625-634
9. Antony AC (1996) Folate receptors. Ann Rev Nutr 16:501-521
10. Baidoo KE, Lin KS et al (1998) Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem 9:218-225
11. Bartholoma MD, Louie AS et al (2010) Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem Rev 110:2903-2920
12. Bauer JA, Morrison BH et al (2002) Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Natl Cancer Inst 94:1010-1019
13. 186Re(I) tricarbonyl complexes of N-(20-hydroxybenzyl)-2-amino- 2-deoxy-D-glucose. B. Bioconjug Chem 15:923-926
14. Begent RH, Verhaar MJ et al (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2:979-984
15. Behr TM, Becker WS et al (1996) Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 37:829-833
16. Behr TM, Gotthardt M et al (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189-200
17. Behr TM, Sharkey RM et al (1995) Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 55:3825-3834
18. Bernard BF, Krenning EP et al (1997) D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 38:1929-1933
19. Birchler MT, Thuerl C et al (2007) Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol Head Neck Surg 136:543-548
20. Blomquist L, Flodh H et al (1969) Uptake of labelled vitamin B12 and 4-iodophenylalanine in some tumors of mice. Experientia 25:294-296
21. Boeggeman E, Ramakrishnan B et al (2009) Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem 20:1228-1236
22. Brack SS, Dinkelborg LM et al (2004) Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging 31:1327-1341
23. 111In-labeledDTPA- orDOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43:1650-1656
24. Brekken RA, Huang X et al (1998) Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58:1952-1959
25. Bruehlmeier M, Garayoa EG et al (2002) Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol 29:321-327
26. 18F]5-fluoro-2-deoxyuridine- PET for imaging of malignant tumors and for measuring tissue proliferation. Cancer Biother Radiopharm 18:327-337
27. Buchsbaum DJ (1995) Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 55:5729s-5732s
28. Buchsbaum DJ (1997)Experimental tumor targetingwith radiolabeled ligands.Cancer 80:2371-2377
29. Carnemolla B, Neri D et al (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 68:397-405
30. 99mTc-MAMA-propyl-thymidine complex as a potential probe for in vivo visualization of tumor cell proliferation with SPECT. Nucl Med Biol 34:283-291
31. Cescato R, Erchegyi J et al (2008) Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 51:4030-4037
32. Cescato R, Schulz S et al (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502-511
33. Christ E, Wild D et al (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94:4398-4405
34. Collins DA, Hogenkamp HP (1997) Transcobalamin II receptor imaging via radiolabeled diethylene-triaminepentaacetate cobalamin analogs. J Nucl Med 38:717-723
35. Collins DA, Hogenkamp HP et al (1999) Tumor imaging via indium-111-labeled DTPAadenosylcobalamin. Mayo Clin Proc 74:687-691
36. Collins DA, Hogenkamp HP et al (2000) Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. Mayo Clin Proc 75:568-580
37. 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 40:2081-2087
38. de Jong M, Rolleman EJ et al (1996) Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 37:1388-1392
39. 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 34:1228-1238
40. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 30:1134-1139
41. 99mTclabelled peptides. Q J Nucl Med 46:195-205
42. 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318-1325
43. 111Inoctreotide. J Nucl Med 41:1114-1119
44. Delgado R, da Silva JJ (1982) Metal complexes of cyclic tetra-azatetra-acetic acids.Talanta 29:815-822
45. Demartis S, Tarli L et al (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 28:534-539
46. Desbouis D, Struthers H et al (2008) Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward human thymidine kinase type 1. J Med Chem 51:6689-6698
47. Dumas C, Schibli R et al (2003) Versatile routes to C-2- and C-6-functionalized glucose derivatives of iminodiacetic acid. J Org Chem 68:512-518
48. Dupertuis YM, Vazquez M et al (2001) Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res 61:7971-7977
49. 125I]iododeoxyuridine in human xenografted glioblastomas. Eur J Nucl Med Mol Imaging 29:499-505
50. 99mTc. Bioconjug Chem 8:146-154
51. 99mTc-aquation labels peptide to an unprecedented high specific activity. J Nucl Med 40:1913-1917
52. Egli A, Hegetschweiler K et al (1997) Hydrolysis of the organometallic aqua ion factriaquatricarbonylrhenium( I). Mechanism, pKa, and formation constants of the polynuclear hydrolysis products. Organometallics 16:1833-1840
53. 186Re). Bioconjug Chem 17:1321-1329
54. Ferreira CL, Ewart CB et al (2006b) Glucosamine conjugates of tricarbonylcyclopentadienyl rhenium(I) and technetium(I) cores. Inorg Chem 45:6979-6987
55. Ferreira CL, Marques FL et al (2010) Cationic technetium and rhenium complexes with pendant carbohydrates. Appl Radiat Isot 68:1087-1093
56. 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 27:371-376
57. 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 49:899-906
58. Flodh H (1968) Autoradiographic studies on distribution of radiocobalt chloride in pregnant mice. Acta Radiol Ther Phys Biol 7:121-128
59. Flodh H, Ullberg S (1968) Accumulation of labelled vitamin B12 in some transplanted tumours. Int J Cancer 3:694-699
60. Garcia-Garayoa E, Blauenstein P et al (2009) A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging 36:37-47
61. Garcia-Garayoa E, Maes V et al (2006) Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl Med Biol 33:495-503
62. 3 bombesin analogues. Nucl Med Biol 34:17-28
63. 3]-core. Bioconjug Chem 19:2409-2416
64. 99mTc] bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Q J Nucl Med Mol Imaging 51:42-50
65. Gardelle O, Roelcke U et al (2001) [76Br]Bromodeoxyuridine PET in tumor-bearing animals. Nucl Med Biol 28:51-57
66. Gati WP, Misra HK et al (1984) Structural modifications at the 20- and 30-positions of some pyrimidine nucleosides as determinants of their interaction with the mouse erythrocyte nucleoside transporter. Biochem Pharmacol 33:3325-3331
67. Giblin MF, Veerendra B et al (2005) Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer. In Vivo 19:9-29
68. Ginj M, Zhang H et al (2006)Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 103:16436-16441
69. Goldenberg DM, Rossi EA et al (2008) Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49:158-163
70. Good S, Walter MA et al (2008)Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 35:1868-1877
71. Gotthardt M, van Eerd-Vismale J et al (2007) Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 48:596-601
72. Gugger M, Reubi JC (1999) Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155:2067-2076
73. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 40:1563-1569
74. Hammond PJ, Wade AF et al (1993) Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 67:1437-1439
75. Heppeler A, Froidevaux S et al (1999) Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptormediated internal radiotherapy. Chem-Eur J 5:1974-1981
76. 131I-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13:187-191
77. 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 44:823-831
78. Hong H, Sun J et al (2008) Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomark Insights 3:435-451
79. 2 GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 21:155-166
80. Josten A, Haalck L et al (2000) Use of microbial transglutaminase for the enzymatic biotinylation of antibodies. J Immunol Methods 240:47-54
81. +. Inorg Chem 21:2037-2040
82. Ke CY, Mathias CJ et al (2003) The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol 30:811-817
83. Ke CY, Mathias CJ et al (2004) Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev 56:1143-1160
84. Khan MU, Morse M et al (2008) Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging 52:441-454
85. King DJ, Turner A et al (1994) Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 54:6176-6185
86. Kobayashi H, Sakahara H et al (1994) Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J Nucl Med 35:1677-1684
87. Körner M, Stockli M et al (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736-743
88. Kwekkeboom D, Krenning EP et al (2000) Peptide receptor imaging and therapy. J Nucl Med 41:1704-1713
89. 99mTc(I)- postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem 13:599-604
90. 177Lulabeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47:1144-1152
91. 99mTc-based radiopharmaceutical. Bioconjug Chem 13:1200-1210
92. Lei K, Rusckowski M et al (1996) Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. Nucl Med Biol 23:917-922
93. Leyton JV, Olafsen T et al (2008) Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 14:7488-7496
94. 111Indium-1,4,7,10-tetraazacyclododecane-N, N', N", N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Cancer Res 55:5726s-5728s
95. Liu S (2008) Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 60:1347-1370
96. Liu S (2009) Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20:2199-2213
97. 99mTc-Labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99:2235-2268
98. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjug Chem 9:583-595
99. 99mTc-labeled cyclic RGDfK tetramer. Nucl Med Biol 35:111-121
100. Liu Z, Li ZB et al (2009a) Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med 50:1168-1177
101. Liu Z, Niu G et al (2009b) 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPRtargeted tumor imaging. Eur J Nucl Med Mol Imaging 36:1483-1494
102. Low PS, Henne WA et al (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120-129
103. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 50:2017-2024
104. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem 49:1833-1836
105. 99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 34:1804-1814
106. 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 29:742-753
107. Mansi R, Wang X et al (2009) Evaluation of a 1,4,7,10- tetraazacyclododecane-1,4,7,10- tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with singlephoton emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240-5249
108. Mardirossian G, Wu C et al (1993) The stability in liver homogenates of indium-111 and yttrium- 90 attached to antibody via two popular chelators. Nucl Med Biol 20:65-74
109. Maresca KP, Hillier SM et al (2009) Comprehensive radiolabeling, stability, and tissue distribution studies of technetium-99m single amino acid chelates (SAAC). Bioconjug Chem 20:1625-1633
110. Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59:1152-1159
111. Mathias CJ, Wang S et al (1998) Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med 39:1579-1585
112. 131I-labeled 5-halo- 1-(2-fluoro-2-deoxy-beta- D-ribofuranosyl)uracils. J Med Chem 32:1289-1294
113. Mindt TL, Jungi V et al (2008) Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjug Chem 19:271-278
114. Minko T, Paranjpe PV et al (2002) Enhancing the anticancer efficacy of camptothecin using biotinylated poly (ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 50:143-150
115. Moody TW, Russell EK et al (1983) Bombesin-like peptides in small cell lung cancer: biochemical characterization and secretion from a cell line. Life Sci 32:487-493
116. Müller C, Brühlmeier M et al (2006a) Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo. J Nucl Med 47:2057-2064
117. Müller C, Mindt TL et al (2009) Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy. Eur J Nucl Med Mol Imaging 36:938-946
118. 99mTc-EC20 in xenografted and syngeneic tumor-bearing mice. Mol Pharm 7:597-604
119. 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer. J Nucl Med 49:623-629
120. 3-folates. Bioconjug Chem 17:797-806
121. 188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Nucl Med Biol 34:595-601
122. Munch-Petersen B, Cloos L et al (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35:69-89
123. Neri D, Carnemolla B et al (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15:1271-1275
124. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30:247-258
125. 99mTc: a preclinical study. J Med Chem 48:100-110
126. 99mTc. J Med Chem 49:4767-4776
127. Oh P, Li Y et al (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429:629-635
128. 99mTc- labelled 5-thio-D-glucose. Nucl Med Commun 20:1055-1058
129. Parker N, Turk MJ et al (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293
130. 99mTc and Re precursors and fundamental NMR investigations. Chemistry 7:1868-1873
131. Pini A, Viti F et al (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273:21769-21776
132. Posey JA, Khazaeli MB et al (2001) A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16:125-132
133. 99mTc-labeling of small biomolecules. Bioconjug Chem 14:720-727
134. 99mTc-EC20 for imaging folate receptorpositive tumors. J Nucl Med 45:857-866
135. Reubi JC, Waser B et al (1998) Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42:546-550
136. 99mTc-1- thioglucose in rats: effect of administration route on pancreatic specificity. Radiology 124:837-838
137. Rolleman EJ, Valkema R et al (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9-15
138. Rowland DJ, Cherry SR (2008) Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 38:209-222
139. Russell-Jones G, McTavish K et al (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98:1625-1633
140. Salmaso S, Pappalardo JS et al (2009) Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers. Bioconjug Chem 20:2348-2355
141. 99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. Nucl Med Biol 35:763-768
142. Santimaria M, Moscatelli G et al (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9:571-579
143. Schibli R, Dumas C et al (2005) Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase. Bioconjug Chem 16:105-112
144. 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjug Chem 11:345-351
145. Schibli R, Schubiger PA (2002) Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging 29:1529-1542
146. + and synthesis of tailor-made bifunctional ligand systems. Bioconjug Chem 13:750-756
147. Schmid M, Neumaier B et al (2006) Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog. Nucl Med Biol 33:359-366
148. Schottelius M, Laufer B et al (2009) Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 42:969-980
149. Schottelius M, Wester HJ (2009) Molecular imaging targeting peptide receptors. Methods 48:161-177
150. Schottelius M, Wester HJ et al (2002) Improvement of pharmacokinetics of radioiodinated Tyr3- octreotide by conjugation with carbohydrates. Bioconjug Chem 13:1021-1030
151. 99mTc-protein conjugates. Bioconjug Chem 2:333-336
152. 3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem 19:2432-2439
153. Seetharam B (1999) Receptor-mediated endocytosis of cobalamin (vitamin B12). Annu Rev Nutr 19:173-195
154. Seetharam B, Li N (2000) Transcobalamin II and its cell surface receptor. Vitam Horm 59:337-366
155. Seetharam B, Yammani RR (2003) Cobalamin transport proteins and their cell-surface receptors. Expert Rev Mol Med 5:1-18
156. 125I]iodo- 20-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting. J Nucl Med 46:800-806
157. Shi J, Kim YS et al (2009) Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 20:750-759
158. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem 51:7980-7990
159. 111In-DTPA- folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 44:700-707
160. 2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 30:101-109
161. 3. Ca. Cancer Res 63:4082-4088
162. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res 23:63-70
163. Smith CJ, Volkert WA et al (2003d) Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 30:861-868
164. Smith CJ, Volkert WA et al (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32:733-740
165. Sosabowski JK, Matzow T et al (2009) Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med 50:2082-2089
166. Spanoudaki VC, Ziegler SI (2008) PET and SPECT instrumentation. Handb Exp Pharmacol 185:53-74
167. 99mTclabeled monoclonal antibody G250 preparations. J Nucl Med 40:829-836
168. 186Re(I) for use in imaging and therapy. Dalton Trans 21(4):654-655
169. 2+ labeled substrates for human thymidine kinase 1. I. Inorg Chem 48:5154-5163
170. Struthers H, Spingler B et al (2008) "Click-to-chelate": design and incorporation of triazolecontaining metal-chelating systems into biomolecules of diagnostic and therapeutic interest. Chemistry 14:6173-6183
171. 99mTc]-HYNIC- trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 26:427-432
172. Tolmachev V, Friedman M et al (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50:274-283
173. Torizuka T, Tamaki N et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811-1817
174. Toyohara J, Hayashi A et al (2003) Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. Nucl Med Biol 30:687-696
175. 125I-iodo- 40-thio-20-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med 43:1218-1226
176. Van de Wiele C, Dumont F et al (2000) Technetium-99m RP527, a GRP
177. Verhaar-Langereis MJ, Zonnenberg BA et al (2000) Radioimmunodiagnosis and therapy. Cancer Treat Rev 26:3-10
178. 111In-DTPA]octreotide. J Nucl Med 46:2057-2060
179. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 34:1209-1218
180. Waibel R, Treichler H et al (2008) New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Res 68:2904-2911
181. 99mTclabeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm 6:231-245
182. 111In] DTPA-folate for use as a tumortargeted radiopharmaceutical. Bioconjug Chem 8:673-679
183. Wängler C, Schirrmacher R et al (2009) Simple and convenient radiolabeling of proteins using a prelabeling-approach with thiol-DOTA. Bioorg Med Chem Lett 19:1926-1929
184. Weitman SD, Lark RH et al (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401
185. Wester HJ, Schottelius M et al (2002) Comparison of radioiodinated TOC, TOCA and Mtr- TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 29:28-38
186. 131I]iodobenzylguanidine. J Nucl Med 21:349-353
187. Wilbur DS, Hamlin DK et al (1996) Synthesis and nca-radioiodination of arylstannyl-cobalamin conjugates. Evaluation of aryliodo-cobalamin conjugate binding to transcobalamin II and biodistribution in mice. Bioconjug Chem 7:461-474
188. Xu N, Cai G et al (2009) Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts. Anticancer Res 29:4005-4011
189. Yang W, Cheng Y et al (2009) Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 44:862-868
190. Yim CB, Boerman OC et al (2009) Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic peptide dendrimers. Bioconjug Chem 20:1323-1331
191. Yokota T, Milenic DE et al (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408
192. Yokota T, Milenic DE et al (1993) Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 53:3776-3783
193. Zardi L, Carnemolla B et al (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 6:2337-2342
194. Zhang H, Chen J et al (2004) Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 64:6707-6715
195. Zwanziger D, Khan IU et al (2008) Novel chemically modified analogues of neuropeptide Y for tumor targeting. Bioconjug Chem 19:1430-1438